Harmony Biosciences Eyes Growth Beyond Wakix in 2025

Harmony Biosciences reported its Q4 and full-year earnings yesterday. Annual sales grew 23%, an impressive figure for a single orphan drug with a single indication (Wakix for narcolepsy). Management guided for approximately 18% growth in 2025 and expects this indication alone to surpass $1 billion in annual sales. The company’s long-term potential will become clearer this year, as its Phase 3 trial for ZYN002 is set to report initial data in Q3. ZYN002 was acquired through Harmony’s 2023 purchase of Zynerba, targeting Fragile X which represents a similar patient population to narcolepsy, with no currently approved treatments. A positive result could push Harmony’s stock closer to my fair value estimate of $73.

Watch List

RDDT 7.71%
NTNX 31.52%
CRWD 63.06%
SE 29.38%
SNOW 7.59%
APPF 4.88%
PINS -23.24%

Buy List

SEMR -38.26%
TSM -38.57%
GOOG -51.98%
NYAX -58.66%
MSFT -31.00%
ODD -31.84%
ASR -28.02%
FLYW -38.06%
HRMY -54.53%
YOU -35.24%
ABNB -32.20%
MELI -29.43%
ADBE -40.48%

Hold List

VTEX -18.40%
ZETA -23.56%
CELH 34.60%
TOST 11.93%
CPNG -15.62%
HIMS -16.74%
PAYC -21.31%
MNDY 6.93%
GLBE -22.43%
ZS 27.08%
V -5.03%
ADSK -3.10%
NOW -3.65%
FTNT -5.29%
TEAM -4.39%